EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Deferiprone and Iron–Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects

George J Kontoghiorghes iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24054970 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von George J Kontoghiorghes. Beteiligte Einrichtung: Postgraduate Research Institute of Science, Technology, Environment and Medicine, Limassol 3021, Cyprus. Hauptthemen laut MEDLINE: Iron, Iron Overload. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 263 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The historical insights and background of the discovery, development and clinical use of deferiprone (L1) and the maltol–iron complex, which were discovered over 40 years ago, highlight the difficulties, complexities and efforts in general orphan drug development programs originating from academic centers. Deferiprone is widely used for the removal of excess iron in the treatment of iron overload diseases, but also in many other diseases associated with iron toxicity, as well as the modulation of iron metabolism pathways. The maltol–iron complex is a recently approved drug used for increasing iron intake in the treatment of iron deficiency anemia, a condition affecting one-third to one-quarter of the world’s population. Detailed insights into different aspects of drug development associated with L1 and the maltol–iron complex are revealed, including theoretical concepts of invention; drug discovery; new chemical synthesis; in vitro, in vivo and clinical screening; toxicology; pharmacology; and the optimization of dose protocols. The prospects of the application of these two drugs in many other diseases are discussed under the light of competing drugs from other academic and commercial centers and also different regulatory authorities. The underlying scientific and other strategies, as well as the many limitations in the present global scene of pharmaceuticals, are also highlighted, with an emphasis on the priorities for orphan drug and emergency medicine development, including the roles of the academic scientific community, pharmaceutical companies and patient organizations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IronIron OverloadHumansDeferiproneIron Chelating AgentsDrug DesignPyridonesPyrones

Stichwörter der Autor:innen

accruferdeferipronedrug design, development and useferaccruferric maltoliron deficiency anemiairon metabolismiron overloadiron toxicityiron-maltolorphan diseasesorphan drugsthalassemia

Substanzen

IronDeferiproneIron Chelating AgentsPyridonesmaltolPyrones

Autor:innen und Institutionen

  • Postgraduate Research Institute of Science, Technology, Environment and Medicine, Limassol 3021, Cyprus.

ORCID-Profile: George J Kontoghiorghes

Zitieren

APA

Kontoghiorghes, G. J. (2023). Deferiprone and Iron–Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24054970

Vancouver

Kontoghiorghes GJ. Deferiprone and Iron–Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24054970

BibTeX
@article{Kontoghiorghes2023,
  author = {Kontoghiorghes, George J},
  title = {Deferiprone and Iron–Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24054970}
}
Kostenlos starten →